Background and Purpose-The contribution of neuroinflammation and, in particular, the infiltration of the brain by lymphocytes is increasingly recognized as a substantial pathophysiological mechanism after stroke. The interaction of lymphocytes with endothelial cells and platelets, termed thromboinflammation, fosters microvascular dysfunction and secondary infarct growth. Siponimod is an S1PR (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment. We investigated the effect of treatment with siponimod on stroke outcome in a mouse model of cerebral ischemia. Methods-Transient middle cerebral artery occlusion was induced in middle-aged wild-type mice. Animals were either treated with siponimod (3 mg/kg; intraperitoneal) or vehicle for 6 days. Stroke outcome was assessed by magnetic resonance imaging (spleen volume: prestroke, day 3, and day 7; infarct volume: days 1, 3, and 7) and behavioral tests (prestroke, day 2, and day 6). Immune cells of the peripheral blood and brain-infiltrating cells ipsilateral and contralateral were analyzed by VETScan and by flow cytometry. Results-Siponimod significantly induced lymphopenia on day 7 after transient middle cerebral artery occlusion and reduced T-lymphocyte accumulation in the central nervous system. No effect was detected for lesion size. Conclusions-For siponimod administered at 3 mg/kg in transient middle cerebral artery occlusion mouse model, our findings do not provide preclinical evidence for the use of S1PR1/5 modulators as neuroprotectant in stroke therapy. Visual Overview-An online visual overview is available for this article.
Immunomodulation as Treatment Option: Infiltration Time Course/Secondary Injury
Stroke remains the second leading cause of deaths worldwide, and therapeutic options are still limited to intravenous tissue-type plasminogen activator and endovascular thrombectomy. These approved therapies only target at reperfusion by opening the blocked vessel. A variety of poststroke immunologic changes lead to complications such as the increased risk of bacterial infections, for example, pneumonia, that favor a bad outcome and increase 30-day mortality. Thus, neuroprotective or immunomodulatory therapies after stroke seem a promising therapeutic option to reduce complications. Various clinical trials reviewed by Veltkamp and Gill 1 aiming at immunomodulation such as treatments with minocycline (NeuMAST study [Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial]), recombinant neutrophil inhibitory factor (ASTIN study [Acute Stroke Therapy by Inhibition of Neutrophils]), the treatment with murine anti-ICAM-1 (intercellular adhesion molecule 1) enlimomab (EAST study [Enlimomab Acute Stroke Trial]) were terminated because of no benefit or adverse effects for patients. Treatment with IL (interleukin)-1RA was effective in reducing infarct volume in preclinical studies by 36% but failed to improve patients' outcome in a phase 2 study (SCIL-STROKE study [Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke]). 2 Treatment with natalizumab, which prevents immune cell infiltration into the brain via prevention of diapedesis, was effective in preclinical studies but failed to reduce infarct growth in patients with stroke (Phase 2 ACTION trial [Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke trial]). 3 Interestingly, treatments aiming at the modulation of lymphocyte egress by fingolimod seem to improve clinical outcomes 4, 5 ; this result raises high interest in the outcome of siponimod treatment in experimental stroke.
It is known that immune cell infiltration enhances brain damage in experimental stroke. This has been shown on one the hand by immune cell depletion having beneficial effects and on the other hand by T-cell activation having detrimental effects. 6, 7 Splenectomy before stroke induction leads to decreased infarct volumes in young and aged mice. It reduced infiltration of peripheral immune cells into the brain and improved disease outcome. 8 However contradictory results have been obtained in different experimental models using more subtle interventions. To investigate the importance of T-cell infiltration for brain lesion development and functional outcome in middle-aged mice, we took advantage of the selective inhibition of lymphocyte function by the novel S1PR (sphingosine-1-phosphate receptor) inhibitor siponimod.
Studies With Siponimod/Fingolimod (Experimental Autoimmune Encephalomyelitis/ Multiple Sclerosis, Stroke)
Among the S1PR modulators, fingolimod has been tested in various preclinical studies of experimental stroke with mixed results. [9] [10] [11] [12] Similar to fingolimod, siponimod is an S1PR modulator. Unlike fingolimod, which needs to be cleaved, siponimod is the active component and binds to 2 of 5 receptor subtypes of S1P: S1PR1 and S1PR5. Modulation/activation leads to phosphorylation, internalization, and degradation of the receptor thus leading to absence and functional antagonism of S1P and the inhibition of lymphocytic egress from the lymph nodes. 13 Moreover, it has been shown that S1P is involved in egress of lymphocytes from the spleen, 14 which also led us to investigate spleen volume.
Recent experimental autoimmune encephalomyelitis studies have shown beneficial effects of siponimod on the infiltration of (autoreactive) lymphocytes into the brain thus reducing disease activity/progression. 15 The phase 2 BOLD study (BAF312 on MRI Lesion Given Once Daily) and its extension and the ongoing phase 3 EXPAND study (Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis) showed the safety of siponimod in patients with multiple sclerosis and reducing disease activity based on magnetic resonance imaging (MRI) showing fewer brain lesions in siponimod-treated multiple sclerosis patients. [16] [17] [18] The primary objective of this study was to investigate the influence of siponimod treatment following experimental stroke on brain lesion size.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Animals and Housing
All animal experiments were approved by local government authorities (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern Nr. 7221.3-1.1-041/17). Mice were bred locally at the Central Service and Research Facility of the University Medicine Greifswald. In our study, we used 12-monthsold male C57Bl/6 N mice to exclude variations because of estrous cycle influences. Two weeks before the start of the experiments, animals were transferred to the Small-Animal MRI facility and allowed to adapt. Mice were group housed with enriched environment (red, transparent plastic boxes and paper rolls). All animals were kept under a 12-hour light/dark cycle (6 AM, 6 PM) and had ad libitum access to standard chow and acidified tap water. Room temperature and humidity were monitored and kept at 22±1°C and 50% to 60 %, respectively. Mean body weight at the beginning of the study (mean and SEM): siponimod, 33.85±0.64 g, versus vehicle, 35.25±0.96 g.
Middle Cerebral Artery Occlusion
The middle cerebral artery occlusion (MCAO) was always performed between 8 and 10 AM. The procedure has been described before. 19 Mice underwent transient MCAO of the left middle cerebral artery with a filament. Anesthesia was induced with 2.5% isoflurane with 1 L/min N 2 0/O 2 mix (ratio, 0.7/0.3) and maintained at 2% isoflurane during surgery. Body temperature was measured with a rectal probe and maintained at ≥36.5°C using a feedback-controlled heating pad. After the ventral cervical skin was incised, the common carotid artery and the external carotid artery were dissected and ligated. A siliconcoated filament (nylon monofilament USP 6-0 with diameters according to manufacturer's suggestion for the animal body weight; Doccol Corporation, MA) was introduced into the common carotid artery and advanced along the internal carotid artery to the origin of the middle cerebral artery. All animals were awake during the occlusion time and reanesthetized for withdrawal of the filament to allow reperfusion. The filament was withdrawn after 45 minutes. The wound was closed with a simple interrupted suture and Lidocaine gel was applied topically for pain relief. The total surgery time did not exceed 15 minutes. Animals were kept in a warming chamber until the next morning and were provided with additional soft, mashed chow in a petri dish on the floor of the chamber, as well as free access to water. After surgery, body temperature and body weight, as well as scoring, were assessed on a daily basis in the morning.
Sequential MRI
Mice undergoing 7T animal MRI (Bruker ClinScan) were anesthetized with 1% to 2% isoflurane and 1 L/min oxygen only. During brain imaging, respiration was monitored, and the animals were kept warm. During abdominal imaging, respiratory gating was applied. Brain scans were performed at days 1, 3, and 7 after experimental stroke induction using 3-dimensional T2-weighted imaging (mouse brain coil: repetition time, 2000 ms; echo time, 37 ms; field of view, 19×25 mm; thickness, 0.45 mm) and additional diffusion-weighted imaging. The spleen was imaged before MCAO and at days 3 and 7 after experimental stroke induction using T2-weighted scanning of the abdomen (whole body coil: repetition time, 1300 ms; echo time, 43 ms; field of view, 42×42 mm; thickness, 0.7 mm).
For evaluation of T2 lesion volume in the brain and spleen volume, MRI data were analyzed by a blinded investigator using OsiriX software (version 4.6; Pixmeo, Switzerland). Regions of interest (spleen and brain infarction) were manually selected, and the volume was calculated semiautomatically. 
Application of Siponimod

Isolation and Fluorescence-Activated Cell Sorter Staining of Brain-Infiltrating Leukocytes
The protocol used for leukocyte isolation was published by Posel et al. 20 Briefly, mice were deeply anesthetized with 3% isoflurane and 1 L/min oxygen and transcardially perfused with cold Hanks' balanced salt solution (w/o Ca/mg) on day 7 after experimental stroke. Immediately before perfusion, blood was collected by cardiac puncture and anticoagulated with EDTA for VetScan analysis.
Brains were harvested, and single hemispheres were mechanically homogenized. The tissue homogenate was enzymatically digested. Brain-infiltrating leukocytes were separated by density centrifugation. Fluorescence-activated cell sorter staining was performed in Trucount tubes (BD Biosciences) according to manufacturer's protocol. First, cells were incubated with TruStain fcX (anti-mouse cluster of differentiation [CD]16/32, clone 93; Biolegend) for 10 minutes at 4°C and subsequently stained with anti-mouse CD45 PerCP-Cy5.5 (30-F11; Biolegend), anti-mouse CD3 APC (allophycocyanin) (17A2; Biolegend), anti-mouse CD4 BV605 (Brilliant Violet) (GK1.5; Biolegend), anti-mouse CD8a fluorescein isothiocyanate (53-6.7; Biolegend), anti-mouse CD19 PE (phycoerythrin)/ Cy7 (cyanine 7) (6D5; Biolegend), anti-mouse Ly-6G (lymphocyte antigen 6 complex locus G6D) APC/Cy7 (1A8; Biolegend) and anti-mouse CD11b V450 (M1/70; BD Biosciences) for 30 minutes at 4°C in the dark. The cells were washed with fluorescence-activated cell sorter buffer and immediately analyzed using a BD LSR II flow cytometer (Becton Dickinson). Data were analyzed using FlowJo 7.5.5.
VetScan Analsysis
Blood samples were immediately transferred to 1.3 mL blood collection microtubes (Sarstedt) for EDTA anticoagulation. Blood parameters were measured using a VetScan HM5 (Abaxis). Following parameters were detected: white blood cell (absolute), lymphocytes (absolute and relative), monocytes (absolute and relative), neutrophils (absolute and relative) and red blood count, hemoglobin (g/dL), hematocrit, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration; red cell distribution width; platelet, platelet hematocrit, mean platelet volume, and platelet distribution width.
Functional Testing
We applied 3 commonly used tests to assess functional disparities because of experimental stroke: corner test, inclined plane, and cylinder test.
21,22 Animals were tested on day 2 before and days 2 and 6 after the experimental induction of stroke.
Corner Test
Two dark plastic boards were put together to form a 30° angle in a box. Intact animals will usually turn around to the right or left randomly, whereas animals with unilateral brain damage will preferentially turn around in the ipsilateral direction, leading with the nonimpaired limb and displaying an asymmetry in corner turning. Ten turns were documented per time point.
Inclined Plane
Mice were placed on a 20° inclined plane. Angle was further increased until mice could no longer stay on the plane and slipped from the plane into a cage with bedding. Test was performed 3× per time point.
Cylinder Test
Mice were placed in a glass cylinder, and the use of forelimbs to explore the cylinder wall was documented for 3 minutes.
Methods to Prevent Bias and Exclusion Criteria
The allocation of individual animal to treatment groups was performed randomly by block randomization. Investigators remained blinded to treatment and group allocation during experiments and data evaluation. Coded siponimod and vehicle controls of identical appearance were prepared by an independent investigator.
Exclusion criteria were unsuccessful stroke induction or nonmiddle cerebral artery territory ischemia based on the brain MRI at day 1 (n Veh =6; n Sip =8). In addition, well-being of animals was scored and mice euthanatized before the end of the study in case they reached the humane end point score.
Only animals that reached the experimental end point (d7) were included, whereas animals that died before the end point (n Veh =5; n Sip =9) or animals that had to be euthanized before the end of the study in case they reached the humane end point score (n Veh =1; n Sip =1) were not included in the final comparison of MRI and blood parameters, leukocyte infiltration, as well as behavior (n Veh =13; n Sip =10).
Statistics
All datasets were tested for deviations from gaussian distribution with the Kolmogorov-Smirnov test. Longitudinal data (body weight, spleen volume, lesion volume, and functional outcome) were tested with 2-way repeated-measures ANOVA and Bonferroni post-tests. Survival was tested using the log-rank test. Other data (brain infiltration and VetScan) were either analyzed with an unpaired t test if they were normally distributed or with a Mann-Whitney U test if the data failed the normality test. Tests were performed with 95% CIs (2 tailed). All analyses were performed with the software GraphPad PRISM 5.0 (GraphPad Software, Inc, San Diego, CA). A P of ≤0.05 was regarded as significant. Values are given as mean±SEM.
Twenty-six animals per group were calculated to detect an existent difference based on a power analysis by G-Power (power, 80%; α=0.05; β=0.2; effect size P=0.8). Stroke lesion size served as primary outcome parameter. An interim analysis was performed. The experiment was stopped at siponimod n day0 =20/n day7 =10 and vehicle n day0 =19/n day7 =13 because a benefit of siponimod treatment could not have been proven by the inclusion of further animals to the calculated group size.
Results
Impact of Systemic Siponimod Treatment on Survival, Lesion Volume, Body Weight, and Spleen Volume
Overall, the observed survival in our study in which we used middle-aged mice was lower than in studies with young mice. This is in accordance with earlier reports. 23, 24 Survival in the siponimod-treated group was 50% by day 7 (n day0 =20; n day7 =10) compared with 68% in the vehicle-treated group (n day0 =19; n day7 =13). Survival was not significantly different in the investigated groups (P=0.3267; Figure 2A ). Lesion volume was determined on days 1, 3, and 7 after experimental stroke induction using T2-weighed MRI of the brain in the siponimod-versus vehicle-treated group. Lesion volume did not differ between the 2 groups (Sip ( Figure 2B ). No significant differences could be detected between vehicle-and siponimod-treated groups regarding the body weight ( Figure 2C ). Relative weight was 75.56±12.68% in siponimod-treated group and 81.10±10.58% in vehicle-treated animals on day 7 after MCAO.
Spleen volume was determined with the help of T2-weighted imaging of the abdomen before stroke and on days 3 and 7 after MCAO. Mean spleen volume was similar in animals of both groups before experimental stroke induction (Sip (prestroke) , 75.41±5.38 mm 3 ; Veh (prestroke) , 76.48±4.13 mm 3 ). Recovery from splenic atrophy on day 7 only tended to be better in vehicle-treated mice than siponimod-treated animals ( Figure 2D ).
Systemic Siponimod Treatment Induced Lymphopenia in Peripheral Blood, As Well As a Reduction of Lymphocytic Infiltration in the Brain
Proportions of white blood cell count populations tended to be lower in siponimod-treated than in vehicle-treated mice on day 7 after experimental stroke (Sip (day 7) , 1.19±0. 17 Figure 3) . Percentage of lymphocytes and monocytes of white blood cells was also significantly reduced in the treatment group (lymphocytes: Sip (day 7) , 8.50±1.04%; Veh (day 7) , 53.62±4.21%; P<0.0001; monocytes: Sip (day 7) , 6.34±1.35%; Veh (day 7) , 9.51±0.72%; P=0.0427). The percentage of neutrophils was significantly enhanced (Sip (day 7) , 85.06±1.94%; Veh (day 7) , 36.87±3.89%; P<0.0001; Figure 4 ).
As expected, siponimod treatment at a dose of 3 mg/kg also reduced the T-cell infiltration into the brain poststroke. On day 7, we found significantly less CD4+ (Sip (day 7) , 1036±179.5; Veh (day 7) , 2257±212.1; P=0.0007) and CD8+ T cells (Sip (day   7) , 2942±343.1; Veh (day 7) , 4897±635.0; P=0.0215) in the ischemic hemisphere of siponimod-treated mice compared with the controls (Figure 5 ). In agreement with the mechanism of action of siponimod, the infiltration of leukocytes (CD45 hi ), neutrophils, microglia, and activated monocytes was not impaired ( Figure 5C ; Figure IA through ID in the online-only Data Supplement). 
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Systemic Administration of Siponimod Did Not Change Functional Outcome
Animals in both the siponimod-treated (n=5) and the vehicle-treated group (n=9) were significantly impaired in their behavior in inclined plane, corner test, and cylinder test after MCAO compared with their pre-MCAO performance.
Behavioral differences between the siponimod and vehicle group were neither detected by corner test, cylinder test, nor inclined plane test after MCAO. Because the animal number for behavior is lower than in the stroke volume analysis, this 
Discussion
Most studies in experimental stroke have been performed on young animals. One approach to overcome the translational roadblock is the use of middle-aged or aged animals in preclinical studies. Only recently, a study has shown that splenectomy in 18-to 22-month-old mice protects from brain injury in experimental stroke by preventing cell infiltration into the brain. 8 Despite a significant lymphopenia, which was apparent in peripheral blood and brain-infiltrating lymphocytes in our study, siponimod-treated (3 mg/kg) animals showed neither neurological improvement nor reduction of lesion size. Body weight did not differ between vehicle and siponimod-treated group. Survival between the siponimod-and vehicle-treated group did not differ significantly, which argues against toxic effects of the treatment with the chosen dosage.
In a traumatic brain injury model, 1 mg/kg i.p. siponimodtreated animals (1 and 4 hours post-traumatic brain injury) showed a reduced lesion volume and improved neurological outcome after 24 hours. In addition, analyses demonstrated an attenuated production of proinflammatory cytokines like IL-1β, TNFα (tumor necrosis factor-α), and significantly attenuated stress-induced protein kinase p38 phosphorylation in siponimod-treated animals. Interestingly, at a higher dose of 3 mg/kg i.p., siponimod had no effect on IL-1β, TNFα, or p38, but the low number of animals in the 3-mg/kg traumatic brain injury group (n=5) hampers the interpretation of the result. Moreover, no results are given for this dosage in other readouts. 25 In contrast, Gergely et al 26 demonstrated that systemic siponimod treatment of 3 mg/kg ameliorates the experimental autoimmune encephalomyelitis disease course better than 0.3 or 0.03 mg/kg dosage. It can be speculated that some effects of siponimod might vary with dosage in dependence of the disease. In consequence, our experiment could be repeated with lower siponimod concentrations.
In addition, we powered the animal numbers in this study for the detection of large effect sizes. Siponimod might still have smaller effects in the treatment of experimental stroke. We also did not study various time points of siponimod administration after MCAO or treatment durations. Also the route of drug administration might be relevant. Whereas Pelz et al 27 administered the drug via drinking water in their myasthenia gravis model and did not detect any disease improvement, Cuzzocrea et al 25 supplied siponimod via intraperitoneal injection, which lead to an improved neurological outcome in brain trauma. Despite an intraperitoneal injection of siponimod, in our study, no significant improvement could be observed.
Although the major immunologic effect of siponimod is thought to be mediated by its inhibition of lymphocyte egress, other mechanisms of action may determine the effect of S1PR modulation in stroke. Preclinical studies demonstrated significant modulation of glial cell function together with reduced lymphocyte infiltration and proinflammatory cytokine expression in the striatum of mice with experimental autoimmune encephalomyelitis applying minipumps allowing continuous intracerebroventricular infusion of siponimod of 0.45 μg/day; indicating its potential success in limiting neurodegenerative pathological processes by direct impact on brain cells in addition to prevention of lymphocyte egress. 15 The stimulation of S1PR5 also preserved the integrity of the blood-brain barrier in traumatic brain injury, as well as in a model of Huntington disease. It increased the expression of BDNF (brain-derived neurotrophic factor), AKT (protein kinase B) kinase, and ERK (extracellular signal-regulated kinase) 28 while preserving occludin. 25 In addition, S1PR5 was shown to regulate the trafficking of patrolling monocytes. 29 In our experiments, blood monocyte amounts were reduced while their infiltration into the brain was not altered.
Moreover, it is of interest to investigate long-term effects of siponimod treatment: T cells are known to show a prolonged activation poststroke. Because T cells also have major effects on cognition, a long-term treatment reducing the lymphocyte infiltration into the brain, it can be hypothesized that cognitive outcome may be improved by inhibition of T-cell migration.
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Conclusions
Our data demonstrate that in our experimental stroke model using middle-aged mice, the inhibition of T-cell infiltration into the ischemic brain hemisphere by siponimod administered at 3 mg/kg during the acute phase of 5 days poststroke is not sufficient to reduce stroke lesion volume.
